Biogaia AB
STO:BIOG B
Biogaia AB
STO:BIOG B
Price:
117.9
SEK
0.34%
Market Closed
Market Cap:
kr11.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Biogaia AB
STO:BIOG B
|
SE |
Multiples-Based Value
The
Multiples-Based Value for
Biogaia AB (BIOG B)
under the Base Case is
112.14
SEK.
Compared with the current market price of 117.9 SEK, the stock appears
Overvalued by 5%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BIOG B
Multiples-Based Value
112.14
SEK
Overvaluation 5%
Multiples Across Competitors
BIOG B Competitors Multiples
Biogaia AB Competitors
Biogaia AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Biogaia AB
STO:BIOG B
|
11.9B SEK | 7.8 | 35.8 | 23.3 | 24.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 5 | 23.6 | 13.8 | 13.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.4 | 18.8 | 11.8 | 14.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9 | 27.2 | 20.4 | 21.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 5 | 16.1 | 11.5 | 13.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.4 | 36.7 | 39.5 | 40.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.7 | 29.8 | 10.2 | 12.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
